000057795 001__ 57795
000057795 005__ 20200221144258.0
000057795 0247_ $$2doi$$a10.2147/IJN.S116479
000057795 0248_ $$2sideral$$a97104
000057795 037__ $$aART-2016-97104
000057795 041__ $$aeng
000057795 100__ $$aRodriguez-Nogales, A.
000057795 245__ $$aIntestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats
000057795 260__ $$c2016
000057795 5060_ $$aAccess copy available to the general public$$fUnrestricted
000057795 5203_ $$aBackground: Current treatment of inflammatory bowel disease is based on the use of immunosuppressants or anti-inflammatory drugs, which are characterized by important side effects that can limit their use. Previous research has been performed by administering these drugs as nanoparticles that target the ulcerated intestinal regions and increase their bioavailability. It has been reported that silk fibroin can act as a drug carrier and shows anti-inflammatory properties. Purpose: This study was designed to enhance the interaction of the silk fibroin nanoparticles (SFNs) with the injured intestinal tissue by functionalizing them with the peptide motif RGD (arginine–glycine–aspartic acid) and to evaluate the intestinal anti-inflammatory properties of these RGD-functionalized silk fibroin nanoparticles (RGD-SFNs) in the trinitrobenzenesulfonic acid (TNBS) model of rat colitis. Materials and methods: SFNs were prepared by nanoprecipitation in methanol, and the linear RGD peptide was linked to SFNs using glutaraldehyde as the crosslinker. The SFNs (1 mg/rat) and RGD-SFNs (1 mg/rat) were administered intrarectally to TNBS-induced colitic rats for 7 days. Results: The SFN treatments ameliorated the colonic damage, reduced neutrophil infiltration, and improved the compromised oxidative status of the colon. However, only the rats treated with RGD-SFNs showed a significant reduction in the expression of different pro-inflammatory cytokines (interleukin IL]-1ß, IL-6, and IL-12) and inducible nitric oxide synthase in comparison with the TNBS control group. Moreover, the expression of both cytokine-induced neutrophil chemoattractant-1 and monocyte chemotactic protein-1 was significantly diminished by the RGD-SFN treatment. However, both treatments improved the intestinal wall integrity by increasing the gene expression of some of its markers (trefoil factor-3 and mucins). Conclusion: SFNs displayed intestinal anti-inflammatory properties in the TNBS model of colitis in rats, which were improved by functionalization with the RGD peptide.
000057795 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/AGL2015-67995-C3-3-R$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-2-R
000057795 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000057795 590__ $$a4.3$$b2016
000057795 591__ $$aPHARMACOLOGY & PHARMACY$$b37 / 256 = 0.145$$c2016$$dQ1$$eT1
000057795 591__ $$aNANOSCIENCE & NANOTECHNOLOGY$$b29 / 87 = 0.333$$c2016$$dQ2$$eT2
000057795 592__ $$a1.173$$b2016
000057795 593__ $$aBioengineering$$c2016$$dQ1
000057795 593__ $$aBiomaterials$$c2016$$dQ1
000057795 593__ $$aBiophysics$$c2016$$dQ1
000057795 593__ $$aOrganic Chemistry$$c2016$$dQ1
000057795 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000057795 593__ $$aDrug Discovery$$c2016$$dQ1
000057795 593__ $$aNanoscience and Nanotechnology$$c2016$$dQ2
000057795 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000057795 700__ $$aAlgieri, F.
000057795 700__ $$0(orcid)0000-0001-6995-4302$$aDe Matteis, L.
000057795 700__ $$aLozano-Perez, A.
000057795 700__ $$aGarrido-Mesa, J.
000057795 700__ $$aVezza, T.
000057795 700__ $$0(orcid)0000-0003-1081-8482$$aMartínez de la Fuente, J.$$uUniversidad de Zaragoza
000057795 700__ $$aCenis, J.L.
000057795 700__ $$aGálvez, J.
000057795 700__ $$aRodriguez-Cabezas, M.
000057795 7102_ $$12013$$2765$$aUniversidad de Zaragoza$$bDpto. Química Orgánica$$cÁrea Química Orgánica
000057795 773__ $$g11 (2016), 5945-5958$$pInt. j. nanomed.$$tInternational Journal of Nanomedicine$$x1176-9114
000057795 8564_ $$s1052960$$uhttps://zaguan.unizar.es/record/57795/files/texto_completo.pdf$$yVersión publicada
000057795 8564_ $$s76630$$uhttps://zaguan.unizar.es/record/57795/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000057795 909CO $$ooai:zaguan.unizar.es:57795$$particulos$$pdriver
000057795 951__ $$a2020-02-21-13:30:56
000057795 980__ $$aARTICLE